kaplan–meier method (Rothmans Inc)
90
Structured Review
Rothmans Inc
kaplan–meier method
Kaplan–Meier Method, supplied by Rothmans Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+method/kaplan+meier+method/pm40423789-45-8-11
Average 90 stars, based on 1 article reviews
Kaplan–Meier Method, supplied by Rothmans Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kaplan-meier+method/kaplan+meier+method/pm40423789-45-8-11
Average 90 stars, based on 1 article reviews
kaplan–meier method - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
other:Article Title: Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2 EV study. Article Snippet: PFS and OS were estimated by employing the Kaplan–Meier method with Article Title: TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab. Article Snippet: Background: TERT promoter mutation is one of the most common genomic alterations in urothelial carcinoma (UC).. Its prognostic role on patients’ outcomes is still not clear.. Methods: We performed a single-center retrospective analysis on patients with advanced UC treated with platinum-based chemotherapy or immunotherapy to assess the presence of somatic TERT 124[C>T] and TERT 146 [C>T] mutations and their association with clinicopathologic factors and survival outcomes. Article Title: Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? Article Snippet: Article info Article history: Received 17 February 2023 Received in Revised form 14 May 2023 Accepted 6 July 2023 Available online 21 July 2023 Associate Editor: Laurence Albiges Article Title: Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results Article Snippet: In each cohort, response rates with exact 95% Article Title: Efficacy of intrathecal methotrexate in children with high-risk medulloblastoma over three years: a retrospective study from a single center. Article Snippet: PFS and overall survival (OS) were estimated by the Article Title: Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1). Article Snippet: OS, PFS and PFS2 were estimated using the Kaplan–Meier method with Article Title: Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study. Article Snippet: We utilized the Kaplan–Meier method with |